Matrine inhibits vascular smooth muscle cell proliferation by modulating the expression of cell cycle regulatory genes

Ping ZHU1, Ji-mei CHEN1, Shu-zhen CHEN2, Cheng ZHANG3, Shao-yi ZHENG1, Guang LONG3, Ji Chen2, Zhi-ling ZHOU1, Rui-xin FAN1, Xiao-ping FAN1, Yan-fang CHEN2, Jian ZHUANG1, Zhi-ling ZHOU1

1Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou 510100, China; 2Department of Pharmacology & Toxicology, Wright State University Boonshoft School of Medicine, Dayton, OH 45435, USA; 3Nanhua University School of Medicine, Hengyang 421001, China

Aim: To investigate the effect of matrine on proliferation of vascular smooth muscle cells (VSMCs) and elucidate the underlying mechanisms.

Methods: Rat aortic VSMCs were cultured in medium supplemented with 10% fetal bovine serum and treated with various concentrations (0, 5, 10, 15, and 20 mg/L) of matrine for 72 h. VSMCs proliferation and cell cycle profiling were assessed using a methylene blue incorporation assay and flow cytometry, respectively. The underlying protein signaling mechanisms were determined using Western blot analysis of the expression levels of cell cycle regulatory genes, including p53, p21, p27, cyclin D1, cyclin E, cyclin-dependent kinase 2 and 4 (cdk2, cdk4), and phosphorylated Rb. The involvement of p21 and p27 pathways was further determined using small interfering RNA (siRNA) knockdown.

Results: Matrine inhibited VSMC proliferation in a dose-dependent manner by promoting G1 arrest. The G1 arrest was accompanied by up-regulation of p53 and p21 protein levels, and down-regulation of cyclin D1/cdk4, cyclin E/cdk2 and phosphorylated Rb protein levels. Matrine did not affect p27 expression. Furthermore, the anti-proliferative effect of matrine was abolished by silencing of p21, but not by silencing of p27.

Conclusion: Our data indicate that matrine has an inhibitory effect on VSMC proliferation via up-regulation of the p53/p21 signaling pathway and modulation of other cell cycle regulatory genes.

Keywords: matrine; vascular smooth muscle cells; proliferation; cell cycle; p21; p27; cyclin D1, cyclin E; cdk 2; cdk 4
proliferation. Previous studies demonstrated that statins cause G1 arrest in VSMCs by increasing p27 expression and reducing cyclin E expression\textsuperscript{[15,16]}. Alternatively, rapamycin inhibits VSMC proliferation by inducing a p21-mediated G1 arrest\textsuperscript{[17]}. Cyclin-dependent kinase 2 and 4 (cdk2 and cdk4) and their respective partners, cyclin E and cyclin D, play pivotal roles in cell cycle progression\textsuperscript{[18]}. Cyclin D1/cdk4 and cyclin E/cdk2 mediate phosphorylation of retinoblastoma (Rb) protein. Expression of cyclin D1 seems to be regulated by extracellular mitogens, while expression of cyclin E is controlled by autonomous mechanisms\textsuperscript{[19,20]}. However, cyclin E is thought to promote Rb phosphorylation by cyclin D-cdk4 complexes\textsuperscript{[21]}. A study in cyclin E knockout mice demonstrates that it is essential for cell cycle re-entry\textsuperscript{[22]}. The aim of this study was to determine the effect of matrine on VSMC proliferation and cell cycle progression by modulating the expression of cell cycle regulatory genes.

Materials and methods

Materials
Matrine (purity, >99\%) was obtained from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Rapamycin and all antibodies were purchased from Sigma (St Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM), heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin were obtained from Gibco Life Technologies Inc (Rockville, MD, USA). The siRNA construction kit was purchased from Ambion (Cambridgeshire, UK). The p27 siRNA was purchased from Santa Cruz Biotechnology Inc (Paso Robles, CA, USA). All experimental procedures were approved by the Guangdong Academy of Medical Sciences Research Committee and were in accordance with National Institutes of Health guidelines.

Cell culture
Rat aortic VSMCs were isolated from the intimal-medial layer of the aorta as described previously\textsuperscript{[23,24]}. Briefly, thoracic aortas from 2-month-old male Sprague-Dawley rats were used for explant cultures. Explants were cultured in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin at 37 °C in 5% CO\textsubscript{2}. VSMCs purity was evaluated by morphological analysis and immunocytochemical staining with a monoclonal antibody against smooth muscle α-actin. Prior to treatment, cells were grown to ~75% confluence and incubated in a serum-free medium for 24 h to induce quiescence. VSMCs were cultured and treated as described for proliferation assays. Following 72 h of treatment with matrine (0, 5, 10, 15, and 20 mg/L) or rapamycin (100 ng/L as positive control), VSMCs were harvested with 0.02% EDTA/0.02% trypsin in calcium- and magnesium-free PBS, fixed in 70 % ethanol for 1 h, and treated with 100 μg/mL RNase A for 1 h at 37 °C. Then, cells (5×10\textsuperscript{4} cells/100 μL) were stained with 25 μg/mL propidium iodide (PI) (jingmei Biotech Co Ltd, Shenzhen, China) for 15 min at room temperature in the dark. Cell cycle distribution was analyzed by flow cytometry (FACS Calibur system, Becton& Dickinson; San Jose, CA, USA) as previously described\textsuperscript{[25]}. The number of cells in G0/G1, S, and G2/M phases was expressed as a percentage of total cells.

Western blotting
VSMCs that were cultured and treated with matrine as described above were used for Western blot analysis. Protein concentrations in the cell lysates were determined using a Bicinchoninic acid kit (Sigma). Proteins (30 μg/lane) were fractionated via 10%-12% (w/v) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Milan, Italy). The membranes were incubated overnight with primary antibodies (1:400 dilutions) for p53, p21, p27, cyclin D1, cyclin E, cdk2, cdk4, phosphorylated Rb, or anti-β-actin (1:1000 dilutions) for 1 h. After washing with PBS containing 0.1% (v/v) Tween 20, membranes were incubated with corresponding horseradish peroxidase conjugated secondary antibodies (1:1000 dilutions) for 1 h, followed by exposure using enhanced chemiluminescence detection reagents (Roche Applied Science). Western blots were scanned and quantified using Quantity One software (Bio-Rad Laboratories). Protein levels were normalized relative to β-actin protein levels. Fold changes in protein levels were calculated and compared.

Materials and methods

Cell proliferation analysis
VSMC proliferation was assessed by using methylene blue incorporation assay in 96-well microculture plates, as previously described\textsuperscript{[27]}. Briefly, VSMC monolayer cells were suspended in 0.02% EDTA/0.02% trypsin, calcium- and magnesium-free phosphate-buffered saline (PBS), spun down and resuspended in DMEM medium. Cells (6×10\textsuperscript{3}/100 μL/well) were transferred into 96-well culture plates and cultured in DMEM medium supplemented with 10% FBS and then treated with various concentrations (0, 5, 10, 15, and 20 mg/L) of matrine or rapamycin (100 ng/L, with rapamycin acting as positive control) for 72 h. Cells were then fixed in 10% formaldehyde saline for 30 min, and then incubated with 1 % (w/v) methylene blue in 0.01 mol/L borate buffer (pH 8.5) for 30 min. The remaining dye was washed off by serially dipping the plate into each of four tanks of 0.01 mol/L borate buffer (pH 8.5). To elute the dye, 100 μL of 1:1 (v/v) ethanol and 0.1 mol/L HCl were added to each well. The plates were then gently shaken and absorbance measurements at 650 nm (A\textsubscript{650}) were collected for each well using a microplate photometer (Flow Laboratories Ltd, Irvine, Scotland). The photometer was blanked on the first column of control wells containing elution solvent alone. The percent changes in A\textsubscript{650} were calculated and compared.

Cell cycle analysis
VSMCs were cultured and treated as described for proliferation assays. Following 72 h of treatment with matrine (0, 5, 10, 15, and 20 mg/L) or rapamycin (100 ng/L as positive control), VSMCs were harvested with 0.02% EDTA/0.02% trypsin in calcium- and magnesium-free PBS, fixed in 70 % ethanol for 1 h, and treated with 100 μg/mL RNase A for 1 h at 37 °C. Then, cells (5×10\textsuperscript{4} cells/100 μL) were stained with 25 μg/mL propidium iodide (PI) (jingmei Biotech Co Ltd, Shenzhen, China) for 15 min at room temperature in the dark. Cell cycle distribution was analyzed by flow cytometry (FACS Calibur system, Becton& Dickinson; San Jose, CA, USA) as previously described\textsuperscript{[25]}. The number of cells in G0/G1, S, and G2/M phases was expressed as a percentage of total cells.

Western blotting
VSMCs that were cultured and treated with matrine as described above were used for Western blot analysis. Protein concentrations in the cell lysates were determined using a Bicinchoninic acid kit (Sigma). Proteins (30 μg/lane) were fractionated via 10%-12% (w/v) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Milan, Italy). The membranes were incubated overnight with primary antibodies (1:400 dilutions) for p53, p21, p27, cyclin D1, cyclin E, cdk2, cdk4, phosphorylated Rb, or anti-β-actin (1:1000 dilutions) for 1 h. After washing with PBS containing 0.1% (v/v) Tween 20, membranes were incubated with corresponding horseradish peroxidase conjugated secondary antibodies (1:1000 dilutions) for 1 h, followed by exposure using enhanced chemiluminescence detection reagents (Roche Applied Science). Western blots were scanned and quantified using Quantity One software (Bio-Rad Laboratories). Protein levels were normalized relative to β-actin protein levels. Fold changes in protein levels were calculated and compared.
Transfection of p21 or p27 siRNA

The siRNA for p21 (5'-GACCAUGUGACCUGUCAC-3', antisense) was synthesized in vitro using the siRNA construction kit (Ambion, Cambridgeshire, UK) as previously reported[30]. Cells were plated at 60% confluency in six-well culture dishes 1 day prior to transfection. Immediately before transfection, cells were washed with PBS. Transfection was carried out using GeneSilencer (PeqLab, Germany) according to the manufacturer’s protocol. Briefly, 1000 ng of p21 or p27 target siRNA (Santa Cruz Biotechnology Inc, Paso Robles, USA) was diluted in a mixture of 25 µL siRNA diluent and 15 µL serum-free medium, and incubated for 5 min at room temperature. The siRNA solution was added to the GeneSilencer and incubated for 5 min at room temperature before the entire solution was added to the cells. Twelve hrs after transfection, the cells were treated with matrine (20 mg/L) for 72 h, and subjected to proliferation and western blot analyses, as described above.

Statistical analysis

The data were expressed as means±standard error of the mean (SEM) and subjected to statistical analysis using the software package SPSS 12.0 (SPSS Inc, Chicago, IL). One-way or two-way ANOVA was used for the analysis of variance. The data were expressed as means±standard error of the mean (SEM) and subjected to statistical analysis using the software package SPSS 12.0 (SPSS Inc, Chicago, IL). One-way or two-way ANOVA was used for the analysis of variance. The variation within a plate was 3.5%. The coefficient of variation in 20 mg/L of matrine, similar to the proliferation inhibition in VSMCs by 65%–75%. Additionally, siRNA-mediated down-regulation of p21 abolished the inhibitory effect of matrine (Figure 4B).

Matrine inhibits VSMCs proliferation

VSMCs proliferation was assessed using the colorimetric assay of methylene blue incorporation. We found that treatment with matrine inhibited VSMCs proliferation in a concentration-dependent manner (Figure 2B). Cell number was significantly lower in 10 mg/L of matrine, and was further decreased in 20 mg/L of matrine, similar to the proliferation inhibition observed following treatment with 100 ng/L of rapamycin. The variation within a plate was 3.5%. The coefficient of variation between plates was 2.5%.

Matrine treatment leads to G1 arrest in VSMCs

Cultured VSMCs were treated with matrine and PI stained for flow-cytometric analysis. The DNA content histograms revealed that matrine led to a G1 phase halt in a dose-dependent manner (Figure 2A). Figure 2B summarizes the effect of matrine on the proportion of G1 phase VSMCs at different concentrations. After treatment with 20 mg/L of matrine, the proportion of G1 phase cells was increased from 84.8%±1.3% to 96.6%±0.8% (n=5/group, P<0.05) and the proportion of S phase cells decreased from 9.9%±1.2% to 1.5%±0.9% (n=5/group, P<0.05). Treatment with matrine at a 20 mg/L concentration induced G1 cell arrest similar to that induced by treatment of 100 ng/L rapamycin.

Matrine upregulates p53 and p21 protein levels, but does not affect p27 protein level

To explore the mechanism by which matrine inhibits VSMCs proliferation, we examined protein levels of p53, p21, and p27 using Western blot analysis. As seen in Figure 3, matrine led to a dose-dependent increase in the expression of p53 and p21. At 20 mg/L, matrine induced increases in p53 and p27 proteins similar to those observed following 100 ng/L rapamycin treatment. Unlike rapamycin, matrine (5–20 mg/L) did not significantly alter the level of p27 protein in VSMCs.

Inhibition of p21, but not p27, rescued matrine-induced proliferation in VSMCs

To determine the roles of p21 and p27 in mediating the anti-proliferation effect of matrine on VSMCs, we transfected the cells with p21 or p27 siRNA 12 h before the cells were treated with matrine (20 mg/L). As seen in Figure 4A, both p21 and p27 siRNAs specifically down-regulated target gene expression in VSMCs by 65%–75%. Additionally, siRNA-mediated down-regulation of p21 abolished the inhibitory effect of matrine on VSMC proliferation. Silencing p27 had no significant influence on the inhibitory effect of matrine (Figure 4B).

Effect of matrine on protein expression levels of cyclin D1, cyclin E, cdk2, cd4, and phosphorylated Rb

To further investigate the mechanism by which matrine leads to G1 arrest in VSMCs, we examined levels of cell cycle regul-
latory proteins, including cyclin D1, cyclin E, cdk2, cd4, and phosphorylated Rb. As seen in Figure 5, matrine decreased levels of cyclin D1, cyclin E, cdk2, and cdk4 and phosphorylated Rb in a dose-dependent fashion. Matrine (20 mg/L) treatment induced increases in protein levels similar to those observed following rapamycin (100 ng/L) treatment.

**Discussion**

To investigate the role of matrine in VSMC proliferation and determine underlying mechanisms, we studied the effect of matrine on 10% FBS-stimulated VSMC proliferation, cell cycle progression, and expression of cell cycle regulatory genes. We found that matrine inhibited VSMC proliferation and reduced cell cycle progression by promoting a G1 phase block. These effects are accompanied by increased levels of p53 and p21, and down-regulation of cyclin D1, cyclin E, cdk 2, cdk4, and phosphorylated Rb protein.

VSMCs cultured in 10% FBS medium are commonly used as an in vitro model to study neointimal proliferation. Under this culture condition, VSMCs undergo tumor-like transformation and proliferation. In previous studies, several tumor cell lines, such as leukemia K562 and hepatocellular carcinoma H22 cells, were incubated with matrine (100–900 mg/L) for 48 h to 4 days. In these cell lines, matrine was able to inhibit cell growth and increase p53 and p21 mRNA expression levels.

We treated cells with lower doses (10–20 mg/L) of matrine because we reasoned that VSMCs would not be as malignant as tumor cells and would therefore be more sensitive to treatment. As we expected, our results show that matrine inhibits the proliferation in transformed VSMCs at these relatively low doses. We also found that matrine elicits its anti-proliferative effect on VSMCs by inducing G 1 phase arrest. In this study, rapamycin was used as a positive control because it has demonstrated anti-proliferative properties in a variety of cell types. Rapamycin inhibits a multifunctional serine-threonine kinase, the mammalian target of rapamycin (mTOR).

Furthermore, our data showed that matrine (20 mg/L) treatment was similar to rapamycin (100 ng/L) treatment because both inhibited VSMC proliferation and induced G1 arrest. These observations demonstrate that matrine is effective in inhibiting VSMC proliferation.

Previous studies demonstrated that statins promote G1 arrest in VSMCs by increasing cellular p27 levels and reducing cyclin E expression. In contrast, rapamycin inhibits VSMC proliferation by halting cells in G1 by up-regulation of p21 protein. To explore the mechanism by which matrine inhibits its proliferation and causes G1 arrest in VSMCs, we first examined protein levels of p53, p21, and p27 in VSMCs following treatment with various concentrations of matrine (0–20 mg/L). Then, we determined the role of p21 and p27 pathways using...
siRNA knockdown to decrease p21 and p27 expression. We found that matrine dose-dependently up-regulated p53 and p21 expression in VSMCs, but it did not affect the expression of p27\(^{[25, 28]}\). SI RNA transfection targeting p21 abolished the inhibitory effect of matrine on VSMC proliferation, whereas, down-regulation of p27 had no influence on matrine’s effect. Expression of p21 can be regulated by both p53 dependent and independent mechanisms\(^{[30–32]}\). In this study, we found that matrine treatment lead to increased p21 protein levels along with increased p53 levels in VSMCs. Therefore, the effect of matrine on p21 expression in VSMCs could be downstream of p53/p21 signaling. As mentioned previously, matrine has effects on multiple cellular functions, including anti-infection, anti-inflammation, anti-cancer activities. Matrine’s anti-proliferative effect on VSMCs deserves further attention.

Mitogen stimulated cell cycle progression in mammalian cells requires the expression and activation of cyclin and cdk complexes\(^{[33]}\). These events are initiated by induction of cyclin D1, followed by induction of cyclin E, activation of cdk 4 and cdk2, and phosphorylation of Rb gene products. Mitogenic activation of cyclin D1/cdk4 and cyclin E/cdk2 during G\(_1\) results in phosphorylation of the Rb protein\(^{[34]}\). Phosphorylated Rb functions as a gatekeeper for the G\(_1\)-S transition by binding and sequestering E2F, a transcription factor that induces the expression of a battery of genes that are necessary for S phase (DNA synthesis). In its unphosphorylated state, Rb binds and sequesters E2F to prevent transcriptional activation of target genes. In this study, we found that matrine decreased levels of cyclin D1, cyclin E, cdk2, cdk4 and phosphorylated Rb in VSMCs in a pronounced manner. These findings are similar to findings from positive controls (rapamycin) and are consistent with previous reports\(^{[17]}\), including a study showing that up-regulation of cyclin E is absolutely required for cell cycle progression in VSMCs cultured in 10% FBS\(^{[22]}\). Since p53/p21 is a negative regulator of cyclins and cdks\(^{[35]}\), our data showing that matrine decreases cyclin D1 and E levels indicate that p53 and p21 may act downstream of matrine to affect cyclins and cdks. P27 is also a negative regulator that inhibits cyclins/cdk4 and Rb phosphorylation, and consequently results in G\(_1\) arrest\(^{[36]}\). Since p27 level did not change following matrine treatment, we do not expect that p27 participate in matrine’s anti-proliferative effect in VSMCs.
In summary, we demonstrated that matrine was a potent inhibitor of VSMC proliferation. Matrine leads to increases in p53 and p21 protein levels, and decreases in cdk2, cdk4, cyclin D1, and cyclin E protein levels. However, whether matrine inhibits intimal hyperplasia must still be investigated in vivo. Additionally, our data do not exclude the possibility that the matrine may exert its effects on VSMCs via affecting other cell cycle proteins such as E2F-1\cite{37}, or other mechanisms that regulate VSMC proliferation.

Acknowledgements
This work was supported by the Major International (Regional) Joint Research Project (2008DFA31140, PZ) and American Diabetes Association (1-10-BS-25, YC). We thank Ms Cathy Graham in the Biomedical PhD Program at Wright State University for her kind help in proof-reading this manuscript.

Author contribution
Ping ZHU, Yan-fang CHEN, and Jian ZHUANG designed research; Ping ZHU, Cheng ZHANG, Shao-yi ZHENG, Zhiling ZHOU, Rui-xin FAN, and Xiao-ping FAN performed research; Shu-zhen CHEN and Ji CHEN contributed new analytical tools and reagents; Ping ZHU, Ji-mei CHEN, and Guang LONG analyzed data; Ping ZHU, Yan-fang CHEN, and Jian ZHUANG wrote the paper.

References
1 Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769–76.
2 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801–9.
3 Zhou Y, Shan H, Qiao G, Sui X, Lu Y, Yang B. Inotropic effects and mechanisms of matrine, a main alkaloid from Sophora flavescens AIT. Biol Pharm Bull 2008; 31: 2057–62.
4 Li Y, Wang B, Zhou C, Bi Y. Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation. Basic Clin Pharmacol Toxicol 2007; 101: 1–8.
5 Li Y, Yang Y, Fang L, Zhang Z, Jin J, Zhang K. Anti-hepatitis activities in the broth of Ganoderma lucidum supplemented with a Chinese herbal medicine. Am J Chin Med 2006; 34: 341–9.
6 Ma L, Ren S, Zhan Y, He Y, Liu X, Jiang J. Anticancer effects of the Chinese medicine matrine on murine hepatocellular carcinoma cells. Planta Med 2008; 74: 245–51.
7 Liu XS, Jiang J. Molecular mechanism of matrine-induced apoptosis in leukemia K562 cells. Am J Chin Med 2006; 34: 1095–103.
8 Zhang L, Wang T, Wen X, Wei Y, Peng X, Li H, et al. Effect of matrine on HeLa cell adhesion and migration. Eur J Pharmacol 2007; 563: 69–76.
9 Dai ZJ, Gao J, Ji ZZ, Wang XJ, Ren HT, Liu XX, et al. Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3. J Ethnopharmacol 2009; 123: 91–6.
10 Zhu MY, Jiang ZH, Lu YW, Guo Y, Gan JJ. Matrine and anti-tumor drugs in inhibiting the growth of human lung cancer cell line. Zhong Xi Yi Jie He Xue Bao 2008; 6: 163–5.
11 Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, et al. Effects of matrine on proliferation and differentiation in K562 cells. Leuk Res 2001; 25: 793–800.
12 Jiang H, Hou C, Zhang S, Xie H, Zhou W, Jin Q, et al. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 2007; 559:

Figure 5. Effect of matrine on the expression of cell cycle regulating proteins in cultured VSMCs examined with Western blot. The levels of cell cycle-related proteins in cultured rat aortic VSMCs were investigated after treatment with various doses of matrine (0, 5, 10, 15 and 20 mg/L) for 72 h. Rapamycin (100 ng/L) was as a positive control. (A) cyclin D1; (B) cyclin E; (C) cdk2; (D) cdk4; (E) Phos-Rb. Results were normalized by the respective level of β-actin. The changes in percentage of treatment control (0 mg/L matrine) were calculated. Data are expressed as mean±SEM. n =5/group, One-way ANOVA. "P<0.05, *P<0.01 vs treatment control.\textsuperscript{b}
13 Sinauridze EI, Kiryev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425–34.

14 Wei JW, Liao JF, Chuang CY, Chen CF, Han PW. Cardiovascular effects of matrine isolated from the Chinese herb Shan-dou-gen. Proc Natl Sci Counc Repub China B 1985; 9: 215–9.

15 Fouty BW, Rodman DM. Mevastatin can cause G<sub>1</sub> arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway. Circ Res 2003; 92: 501–9.

16 Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G<sub>1</sub> arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999; 96: 7797–802.

17 Braun-Dullaeus RC, Mann MJ, Seay U, Zhang L, von Der Leyen HE, Morris RE, et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb Vasc Biol 2001; 21: 1152–8.

18 Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdk's. Biochim Biophys Acta 2001; 1471: M123–M133.

19 Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12: 676–84.

20 Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G<sub>1</sub>/S phase transition. Nat Cell Biol 2005; 7: 831–6.

21 Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003; 15: 158–63.

22 Geng Y, Yu Q, Sicsinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell 2003; 114: 431–43.

23 Corsini A, Verdi D, Rafteri M, Quarato P, Paoletti R, Fumagalli R. Effects of 26-aminomethyl, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol 1995; 15: 420–8.

24 Thyberg J, Palmberg L, Nilsson J, Ksiazek T, Sjolund M. Phenotype modulation in primary cultures of arterial smooth muscle cells. On the role of platelet-derived growth factor. Differentiation 1983; 25: 156–67.

25 Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–23.

26 Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093–9.

27 Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 1989; 92 (Pt 3): 513–8.

28 Ferri N, Granata A, Pirola C, Torti F, Pfister PJ, Dorent R, et al. Fluvasatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 2008; 74: 144–53.

29 Endesfelder S, Kliche A, Loehmuller H, von MA, Speer A. Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts. J Mol Med 2005; 83: 64–71.

30 Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935–44.

31 Takahashi A, Taniguchi T, Ishikawa Y, Yokoyama M. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and p53. Circ Res 1999; 84: 543–50.

32 Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G<sub>1</sub> arrest. Cell 1994; 76: 1013–23.

33 Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672–7.

34 Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131–4.

35 Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 363: 701–4.

36 Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.

37 Jiang H, Hou C, Zhang S, Xie H, Zhou W, Jin Q, et al. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 2007; 559: 98–108.